Global Consensus Statement on Menopausal Hormone Therapy

Villiers, T. J. de; Gass, Margery; Haines, C.J.; Hall, Janet E.; Løbo, Rogerio A.; Pierroz, Dominique D.; Rees, Margaret

doi:10.3109/13697137.2013.771520

Cited by 256 publications

(147 citation statements)

References 0 publications

Supporting

Mentioning

106

Contrasting

Unclassified

Order By: Relevance

“…As a consequence of these findings many women have become reluctant to continue or commence HRT due to fear of adverse risks, which has resulted in a significant decrease in the incidence of breast cancer over the last 10 years [12,13]. Recently, a global consensus statement on menopausal hormone therapy was published which was aimed for women and health care practitioners to make appropriate decisions on the use of HRT [14]. As a result of the effects of HRT, women seek alternative treatment options, particularly complementary and alternative therapies.…”

Section: Introductionmentioning

confidence: 99%

To exercise, or, not to exercise, during menopause and beyond

Stojanovska¹,

Apostolopoulos²,

Polman³

et al. 2014

Maturitas

103

View full text Add to dashboard Cite

Menopausal symptoms in women can be severe and disruptive to overall quality of life. Hormone replacement therapy, is known to be effective in ameliorating symptoms, however, reporting of side effects has resulted in alternative treatment options. Exercise has been assessed as an alternative treatment option for alleviating menopausal symptoms, including, psychological, vasomotor, somatic and sexual symptoms. Here we report the effects of physical activity and exercise on menopause symptoms in menopausal women.

show abstract

Section: Introductionmentioning

confidence: 99%

To exercise, or, not to exercise, during menopause and beyond

Stojanovska¹,

Apostolopoulos²,

Polman³

et al. 2014

Maturitas

103

View full text Add to dashboard Cite

show abstract

“…The early menopause is defined as the irreversible cessation of the menstruations between 40 and 45 years, and the premature menopause or premature ovarian failure as the final menstrual retirement before the age of 40 years. These two groups have medical connotations that is totally different in comparison to women who present menopause in the physiological age group [3,4,9].…”

mentioning

confidence: 99%

“…The menopausal hormone therapy (MHT) is the principal therapeutic tool, with the aim to contribute estrogens to suppress the clinical symptomatology and to make a favorable impact on the estrogen-dependent tissues [3,6,7,9]. In the pronouncement of the North American Menopause Society of 2010 [6] about MHT in premature menopause indicated that 'There are inadequate data regarding MHT in these populations.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Early and premature menopause in women with diabetes mellitus Type 2

Monterrosa-Castro

Portela-Buelvas

Blümel-Méndez³

2014

Expert Review of Endocrinology & Metabolism

View full text Add to dashboard Cite

“…El SGM puede afectar hasta el 50% de las mujeres posmenopáusicas, sus síntomas tienden a ser crónicos y progresivos (2)(3)(4)(5)(6)(7)(8), afectando la sexualidad y la calidad de vida (9)(10)(11)(12)(13)(14)(15). Algunas preparaciones, incluidos lubricantes y humectantes mejoran los sínto-mas, sin embargo proporcionan un alivio temporal.…”

Section: Introductionunclassified

Láser erbium vaginal como tratamiento del síndrome genitourinario de la menopausia: resultados preliminares

Gambacciani

2015

Rev. chil. obstet. ginecol.

View full text Add to dashboard Cite

RESUMENAntecedentes: El síndrome genitourinario de la menopausia (SGM) afecta hasta el 50% de las mujeres posmenopáusicas. Sus síntomas presentan un curso crónico y progresivo, pudiendo alterar significativamente la sexualidad y la calidad de vida. Objetivo: Evaluar efectividad a corto plazo y aceptabilidad del láser vaginal de Erbium en cristal de itrio-aluminio-granate (Er:YAG) como una terapia fototérmica no invasiva, no ablativa para el manejo del SGM. Método: Estudio longitudinal prospectivo, realizado en 28 mujeres posmenopáusicas con SGM. Se aplica láser vaginal Er:YAG en 3 sesiones cada 30 días. En todos los controles, se evalúa sequedad vaginal, dispareunia mediante escala visual analógica, y se registra el "vaginal health index score" (VHIS). Al final del tratamiento se evalúa la aceptabilidad del método. Resultados: Se observa mejoría significativa de los síntomas (sequedad vaginal y dispareunia; p<0,01) durante todo el periodo de estudio y del VHIS (8,2 ± 1,3 previo al tratamiento vs. 19,2 ± 0,4 posterior al tratamiento; p<0,01). El 93,4% de las pacientes calificó el procedimiento como excelente o bueno. Conclusión: Nuestro estudio piloto muestra que el tratamiento con láser Er:YAG en mujeres posmenopáusicas con síntomas de SGM es eficaz, factible y seguro en el corto plazo. Se requieren datos a más largo plazo y de mayor tamaño muestral para confirmar nuestros resultados.PALABRAS CLAVE: Menopausia, estrógenos, láser Erbium, atrofia vulvovaginal, síndrome genitourinario de la menopausia SUMMARY Background:The genitourinary syndrome of menopause (GSM) affects up to 50% of postmenopausal women. Symptoms are chronic and likely worsen over time. This complains may interfere with sexual function and quality of life. Objective: To evaluate the short-term effectiveness and acceptability of Erbium in yttrium aluminum-garnet crystal Laser (Er:YAG) as a non-invasive, non-ablative photothermal therapy for the treatment of GSM. Methods: Prospective longitudinal study performed in 28 postmenopausal women suffering from GSM. All participants were treated intravaginally with Er:YAG laser in 3 applications performed every 30 days. Symptoms (vaginal dryness and dyspareunia) were evaluated by a visual-analogic scale (VAS) and the vaginal health index score (VHIS). After therapy, the women were asked to evaluate the acceptability of the intervention. Results: Er:YAG laser treatment was effective to improve symptoms (vaginal dryness and dyspareunia; p<0.01) at all the study period, as well the VHIS (8.2 ± 1.3 at baseline vs. 19.2 ± 0.4 after treatment; p<0.01). Satisfaction with the procedure was reported as excellent or good by 93.4% of women. Conclusion: Our pilot study shows that the Er:YAG treatment in postmenopausal women with GSM is effective, feasible, and safe. Further larger, long-term and controlled studies are required to confirm this data.

show abstract

Global Consensus Statement on Menopausal Hormone Therapy

Cited by 256 publications

References 0 publications

To exercise, or, not to exercise, during menopause and beyond

To exercise, or, not to exercise, during menopause and beyond

Early and premature menopause in women with diabetes mellitus Type 2

Láser erbium vaginal como tratamiento del síndrome genitourinario de la menopausia: resultados preliminares

Contact Info

Product

Resources

About